Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1978 May;37(5):818–826. doi: 10.1038/bjc.1978.120

Cellular Immunity to Encephalitogenic Factor as Measured by Macrophage Migration Inhibition During Tumour Induction and Growth

D J Flavell, J Goepel, C W Potter, I Carr
PMCID: PMC2009606  PMID: 77674

Abstract

Spleen-cell sensitivity to encephalitogenic factor (EF) was measured with the macrophage migration inhibition (MMI) test over a period of time in hamsters inoculated with SV40-transformed tumour cells and in rats treated with 4-dimethylamino-3′-methylazobenzene.

Spleen cells from hamsters receiving 10 or 103 SV40 tumour cells gave inhibition of macrophage migration with EF at a significance level of P<0·05 21 days after implantation. Spleen cells from animals receiving 105 tumour cells gave inhibition at a significance level of P<0·001 after the same interval.

Spleen-cell sensitivity to EF, and the abrogation of this sensitivity by serum, was investigated over a period of time in rats undergoing hepatocarcinogenesis. Sensitivity to EF was seen in 2/10 animals (20%) with minimal lesions of the liver, in 2/16 animals (12%) with proliferative changes and/or cholangiofibrosis, in 7/15 animals (46%) with dysplastic lesions of portal-tract epithelial cells and in all 5 animals with cholangiocarcinoma. None of a control group of 10 animals showed any response to EF. Autologous serum abrogated the spleen-cell response to EF in one sensitized animal with proliferative changes and cholangiofibrosis, in all 7 sensitized animals with dysplastic hepatic lesions and in 4/5 sensitized animals with cholangiocarcinoma. Autologous serum had no effect on macrophage migration in the 10 control animals.

These findings indicate that a progressive increase in sensitization to EF occurs during carcinogenesis and is evident at the point of preneoplastic dysplasia. This has an obviously important bearing on the clinical use of such tests.

Full text

PDF
818

Images in this article

821Fig. 1A
on p.821
821Fig. 1B
on p.821
822Fig. 1C
on p.822

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernard C. C., Lamoureux G. Inhibition by serum of encephalitogenic activity of myelin basic protein: nature of the serum factor responsible. Cell Immunol. 1975 Mar;16(1):182–191. doi: 10.1016/0008-8749(75)90197-5. [DOI] [PubMed] [Google Scholar]
  2. Boyd H., Louis C. J., Martin T. J. Activity and hormone responsiveness of adenyl cyclase during induction of tumors in rat liver with 3'-methyl-4-dimethylaminoazobenzene. Cancer Res. 1974 Jul;34(7):1720–1725. [PubMed] [Google Scholar]
  3. Bray A. E., Holt P. G. Serum blocking factor as an index of metastatic spread following primary tumour excision. Eur J Cancer. 1975 Dec;11(12):855–860. doi: 10.1016/0014-2964(75)90084-5. [DOI] [PubMed] [Google Scholar]
  4. Caspary E. A., Field E. J. Specific lymphocyte sensitization in cancer: is there a common antigen in human malignant neoplasia? Br Med J. 1971 Jun 12;2(5762):613–617. doi: 10.1136/bmj.2.5762.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Currie G. The role of circulating antigen as an inhibitor of tumour immunity in man. Br J Cancer Suppl. 1973 Aug;1:153–161. [PMC free article] [PubMed] [Google Scholar]
  6. Field E. J., Caspary E. A., Shepherd R. T. Immunodiagnosis of cancer. Br Med J. 1972 Sep 9;3(5827):641–642. doi: 10.1136/bmj.3.5827.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Flavell D. J., Potter C. W. Cellular immunity to encephalitogenic factor in man as measured by the macrophage migration inhibition test: the effects of serum. Br J Cancer. 1978 Jan;37(1):15–22. doi: 10.1038/bjc.1978.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Light P. A., Preece A. W., Waldron H. A. Studies with the macrophage migration inhibition (MMI) test in patients with malignant disease. Clin Exp Immunol. 1975 Nov;22(2):279–284. [PMC free article] [PubMed] [Google Scholar]
  9. Mitchell H. Structural conformation of tumour antigen. Lancet. 1973 May 12;1(7811):1061–1061. doi: 10.1016/s0140-6736(73)90698-3. [DOI] [PubMed] [Google Scholar]
  10. PRICE J. M., HARMAN J. W., MILLER E. C., MILLER J. A. Progressive microscopic alterations in the livers of rats fed the hepatic carcinogens 3'-methyl-4-dimethylaminoazobenzene and 4'-fluoro-4-dimethylaminoazobenzene. Cancer Res. 1952 Mar;12(3):192–200. [PubMed] [Google Scholar]
  11. Pasternak L., Jenssen H. L., Köhler H., Pasternak G. Cross-reactions among mouse tumors of different etiology as detected by macrophage electrophoretic mobility (MEM) test. Eur J Cancer. 1976 May;12(5):389–393. doi: 10.1016/0014-2964(76)90177-8. [DOI] [PubMed] [Google Scholar]
  12. Pritchard J. A., Moore J. L., Sutherland W. H., Joslin C. A. Clinical assessment of the MOD-MEM cancer test in controls with non-malignant diseases. Br J Cancer. 1976 Jul;34(1):1–6. doi: 10.1038/bjc.1976.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pritchard J. A., Moore J. L., Sutherland W. H., Joslin C. A. Technical aspects of the macrophage electrophoretic mobility (MEM) test for malignant disease. Br J Cancer Suppl. 1973 Aug;1:229–236. [PMC free article] [PubMed] [Google Scholar]
  14. RICHARDSON H. L., BORSOS-NACHTNEBEL E. Study of liver tumor development and histologic changes in other organs in rats fed azo dye 3-methyl-4-dimethylaminoazobenzene. Cancer Res. 1951 Jun;11(6):398–403. [PubMed] [Google Scholar]
  15. Reddy K. P., Buschmann R. J., Chomet B. Cholangiocarcinomas induced by feeding 3'-methyl-4-dimethylaminoazobenzene to rats. Histopathology and ultrastructure. Am J Pathol. 1977 Apr;87(1):189–204. [PMC free article] [PubMed] [Google Scholar]
  16. Rees R. C., Potter C. W. Immune response to adenovirus 12-induced tumour antigens, as measured in vitro by the macrophage migration inhibition test. Eur J Cancer. 1973 Jul;9(7):497–502. doi: 10.1016/0014-2964(73)90134-5. [DOI] [PubMed] [Google Scholar]
  17. Shelton J. B., Potter C. W., Carr I. Cellular immunity to myelin basic protein in man and in animal model systems as measured by the macrophage migration inhibition test. Br J Cancer. 1975 May;31(5):528–534. doi: 10.1038/bjc.1975.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Singer A., Shelton J., Hill S., Potter C. Cellular immunity to human basic myelin protein in women with dysplasia and carcinoma in situ of the cervix. Br J Obstet Gynaecol. 1975 Oct;82(10):820–825. doi: 10.1111/j.1471-0528.1975.tb00580.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES